SUPN - MCAP CO - Supernus Pharmaceuticals

The market valuation visualization for Supernus Pharmaceuticals (SUPN) shows a capitalization of 2.48. Business stability in the US is guaranteed by patent protection and an absence of political risks. Supernus Pharmaceuticals (SUPN) focuses on ethical R&D to combat psychiatric disorders, attracting leading neurobiologists. Primary revenue is generated through the supply of specialized drugs to insurance funds for the therapy of ADHD and epilepsy.

Patent protection for CNS drugs provides Supernus Pharmaceuticals (SUPN) with significant pricing power, directly impacting the investment attractiveness of its assets. Analyzing the company's current market capitalization, an investor assesses the aggregate value of all shares as an indicator of the business's market scale, where breaking through price levels signals either an expansion of fundamental value or an increase in the risk of capital loss.